{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:00:15Z","timestamp":1789754415208,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.critrevonc.2022.103644","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:40:33Z","timestamp":1645789233000},"page":"103644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma"],"prefix":"10.1016","volume":"172","author":[{"given":"Charles J.","family":"Milrod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103644_bib1","unstructured":"Annual Estimates of the Resident Population by Sex, Race, and Hispanic Origin: April 1, 2010 to July 1, 2019, US Census. Accessed February 22 2021."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103644_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103644_bib3","unstructured":"Chan S., Reddy V., Myers B. et al., 2020. Underrepresentation of skin of color images in dermatology and medical journals from 2008 to 2018. Presented at the 16th Annual Skin of Color Society 2020 Symposium. Denver, CO, 19 March 2020."},{"key":"10.1016\/j.critrevonc.2022.103644_bib4","unstructured":"ClinicalTrials.gov [Internet], 2019d. Bethesda (MD): National Library of Medicine (US). Identifier NCT01109004, Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702); 2019d Sep 25."},{"key":"10.1016\/j.critrevonc.2022.103644_bib5","unstructured":"ClinicalTrials.gov [Internet], 2019c. Bethesda (MD): National Library of Medicine (US). Identifier NCT02880228, Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant; 2019c July 30."},{"key":"10.1016\/j.critrevonc.2022.103644_bib6","unstructured":"ClinicalTrials.gov [Internet], 2018b. Bethesda (MD): National Library of Medicine (US). Identifier NCT01794039, Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide; 2018b Aug 21."},{"key":"10.1016\/j.critrevonc.2022.103644_bib7","unstructured":"ClinicalTrials.gov [Internet], 2019b. Bethesda (MD): National Library of Medicine (US). Identifier NCT00445692, Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma; 2019b Nov 13."},{"key":"10.1016\/j.critrevonc.2022.103644_bib8","unstructured":"ClinicalTrials.gov [Internet], 2018c. Bethesda (MD): National Library of Medicine (US). Identifier NCT01217957, A Study of Ixazomib Administered in Combination With Lenalidomide and Low- Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma; 2018c Mar 14."},{"key":"10.1016\/j.critrevonc.2022.103644_bib9","unstructured":"ClinicalTrials.gov [Internet], 2019e. Bethesda (MD): National Library of Medicine (US). Identifier NCT00622336, A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC- 5013-MM-010 for Subjects With Multiple Myeloma; 2019e Nov 20."},{"key":"10.1016\/j.critrevonc.2022.103644_bib10","unstructured":"ClinicalTrials.gov [Internet], 2016a. Bethesda (MD): National Library of Medicine (US). Identifier NCT00540644, Phase II Study of Revlimid\u00ae, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma; 2016a June 21."},{"key":"10.1016\/j.critrevonc.2022.103644_bib11","unstructured":"ClinicalTrials.gov [Internet]2019h. Bethesda (MD): National Library of Medicine (US). Identifier NCT01142232, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma; 2019h Oct 22."},{"key":"10.1016\/j.critrevonc.2022.103644_bib12","unstructured":"ClinicalTrials.gov [Internet], 2019a. Bethesda (MD): National Library of Medicine (US). Identifier NCT00807599, Lenalidomide (Revlimid\u00ae) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L; 2019a March 15."},{"key":"10.1016\/j.critrevonc.2022.103644_bib13","unstructured":"ClinicalTrials.gov [Internet], 2020c. Bethesda (MD): National Library of Medicine (US). Identifier NCT02322320, Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT); 2020c May 11."},{"key":"10.1016\/j.critrevonc.2022.103644_bib14","unstructured":"ClinicalTrials.gov [Internet]2020a. Bethesda (MD): National Library of Medicine (US). Identifier NCT01858558, Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma; 2020a June 29."},{"key":"10.1016\/j.critrevonc.2022.103644_bib15","unstructured":"ClinicalTrials.gov [Internet], 2019f. Bethesda (MD): National Library of Medicine (US). Identifier NCT01080391, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma; 2019f Jan 14."},{"key":"10.1016\/j.critrevonc.2022.103644_bib16","unstructured":"ClinicalTrials.gov [Internet], 2019g. Bethesda (MD): National Library of Medicine (US). Identifier NCT00689936, Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma; 2019g Nov 20."},{"key":"10.1016\/j.critrevonc.2022.103644_bib17","unstructured":"ClinicalTrials.gov [Internet], 2011. Bethesda (MD): National Library of Medicine (US). Identifier NCT00478777, A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma; 2011 Nov 3."},{"key":"10.1016\/j.critrevonc.2022.103644_bib18","unstructured":"ClinicalTrials.gov [Internet], 2012. Bethesda (MD): National Library of Medicine (US). Identifier NCT00420849, A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma; 2012 May 21."},{"key":"10.1016\/j.critrevonc.2022.103644_bib19","unstructured":"ClinicalTrials.gov [Internet], 2014. Bethesda (MD): National Library of Medicine (US). Identifier NCT00691704, Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy; 2014 Aug 19."},{"key":"10.1016\/j.critrevonc.2022.103644_bib20","unstructured":"ClinicalTrials.gov [Internet], 2017. Bethesda (MD): National Library of Medicine (US). Identifier NCT00619684,Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant; 2017 May 18."},{"key":"10.1016\/j.critrevonc.2022.103644_bib21","unstructured":"ClinicalTrials.gov [Internet] , 2020. Bethesda (MD): National Library of Medicine (US). Identifier NCT01142232, Lenalidomide and Dexamethasone With\/Without Stem Cell Transplant in Patients With Multiple Myeloma; 2020 Feb 5."},{"key":"10.1016\/j.critrevonc.2022.103644_bib22","unstructured":"ClinicalTrials.gov [Internet], 2016b. Bethesda (MD): National Library of Medicine (US). Identifier NCT00560391, Dasatinib in Combination With Revlimid (and Dexamethasone); 2016b Aug 4."},{"key":"10.1016\/j.critrevonc.2022.103644_bib23","unstructured":"ClinicalTrials.gov [Internet], 2018a. Bethesda (MD): National Library of Medicine (US). Identifier NCT01782963 Lenalidomide\/Bortezomib\/Dexamethasone for Multiple Myeloma ((MM)) 2018a.Oct 31."},{"key":"10.1016\/j.critrevonc.2022.103644_bib24","unstructured":"ClinicalTrials.gov [Internet], 2020b. Bethesda (MD): National Library of Medicine (US). Identifier NCT01245673, Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma; 2020b April 6."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103644_bib25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2017-0592","article-title":"Representation of minorities and elderly patients in multiple myeloma clinical trials","volume":"23","author":"Duma","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103644_bib26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/bjd.17608","article-title":"Under-representation of skin of colour in dermatology images: not just an educational issue","volume":"180","author":"Lester","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103644_bib27","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2021010853","article-title":"Incidence of skin hyperpigmentation in black patients receiving treatment with immunomodulatory drugs","volume":"137","author":"Milrod","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103644_bib28","unstructured":"SEER database , 2014a. Rates per 100,000 for Myeloma, SEER Incidence and US Death Rates by Race\/Ethnicity, Figure 18.2."},{"key":"10.1016\/j.critrevonc.2022.103644_bib29","unstructured":"SEER database, 2014b. Estimated United States Cancer Prevalence Counts on January 1. By Race\/Ethnicity, Table 18.21."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:42:38Z","timestamp":1760902958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"alternative-id":["S1040842822000683"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103644","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103644"}}